軟部肉腫の世界市場

軟部肉腫の世界市場は2030年までに24億米ドルに達する

2024年に15億米ドルと推定される軟部肉腫の世界市場は、分析期間2024-2030年にCAGR 7.4%で成長し、2030年には24億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法治療は、CAGR 8.9％を記録し、分析期間終了時には9億470万米ドルに達すると予測されます。化学療法治療分野の成長率は、分析期間中CAGR 5.2％と推定されます。

米国市場は4億1,760万米ドルと推定、中国はCAGR11.8％で成長予測

米国の軟部肉腫市場は、2024年には4億1,760万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 11.8%で推移し、2030年には5億280万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6%と7.2%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界の軟部肉腫市場- 主要動向と促進要因まとめ

複雑性をターゲットに：診断と治療における革新が軟部肉腫管理を変える

軟部肉腫ががん領域における独自の治療課題である理由

軟部肉腫（STS）は、脂肪、筋肉、血管、神経、腱などの結合組織から発生するまれな悪性腫瘍の不均一なグループです。成人がん全体の1％未満を占めるSTSは、脂肪肉腫、平滑筋肉腫、滑膜肉腫、未分化多形肉腫など50以上の組織型に及ぶ。この組織学的多様性は、腫瘍医、病理医、薬剤開発者にとって大きな課題です。早期診断が困難であること、腫瘍の挙動が多様であること、治療介入に対する反応が異なることなどから、標準化された治療はしばしば制限されます。ほとんどの症例は、腫瘍が進行期または転移に達した後に初めて診断されるが、その主な原因は無症候性進行と良性病変との誤分類です。

そのため、病理組織学的および分子生物学的プロファイリングはSTSの診断に不可欠となっています。免疫組織化学、FISH（蛍光in situハイブリダイゼーション）、次世代シークエンシング（NGS）は、腫瘍のサブタイプを正確に特徴付け、実用的な遺伝子変化を同定するために、ますます採用されるようになってきています。分子診断学の進歩により、STS治療に対する個別化アプローチが可能になりつつあります。しかしながら、これらの腫瘍の稀少性と複雑性により、大規模臨床試験の利用可能性は依然として制限されており、その結果、他のがんと比較して承認された標的治療薬の数は少ないです。STS細胞固有の遺伝的不安定性と適応性は、治療戦略をさらに複雑にし、しばしば進行した患者の予後不良をもたらします。

どのような治療戦略や治療開発がSTSの情勢を変えているのか？

限局性軟部肉腫に対する主要な治療法は外科的切除であり、腫瘍の悪性度、部位、切除断端に応じて放射線療法や化学療法が併用されることが多いです。高悪性度肉腫や深在性肉腫では、再発リスクを軽減するために放射線療法（外照射またはブラキセラピー）が行われます。しかしながら、進行性・転移性STSに対する全身療法は、伝統的に有効性に限界があります。ドキソルビシンをベースとした化学療法は、単独またはイホスファミドとの併用で、長らく第一線の標準療法であったが、しばしば重大な毒性を伴い、生存利益はわずかです。

現在、標的治療と免疫療法がSTS治療のパラダイムシフトを牽引しています。マルチチロシンキナーゼ阻害剤であるパゾパニブやDNA結合性抗悪性腫瘍剤であるトラベクテジンなどの薬剤は、サブタイプ特異的な有効性を示しています。例えば、パゾパニブは非脂肪細胞性STSに有効性を示し、エリブリンは脂肪肉腫患者に有望です。さらに、PD-1やCTLA-4チェックポイント阻害剤のような免疫療法は、特に変異の多い未分化多形肉腫や滑膜肉腫のようなサブタイプに対して評価中です。がん精巣抗原を標的とするCAR-T細胞療法やがんワクチンも、前臨床試験や初期段階の臨床試験で検討されています。

精密医療はバイオマーカー主導のアプローチでさらに進歩しています。NTRK融合、ALK再配列、CDK4増幅は新規治療のターゲットとなりつつあり、組織学的には異なるがゲノム的には類似した腫瘍間で薬剤の再利用を可能にしています。コンパニオン診断薬はこれらの治療薬と共同開発され、正確な患者選択を可能にしています。さらに、いくつかの産学共同研究は、募集の課題を克服し、希少なサブタイプ間でより迅速なデータ蓄積を可能にするために、汎肉腫登録と適応試験デザインを推進しています。

地域のヘルスケアシステムと利害関係者は肉腫管理のニーズにどのように対応しているか？

北米と欧州は、診断、調査、治療アクセスにおいて世界の肉腫市場をリードしています。米国では、肉腫専門センターやSARC（Sarcoma Alliance for Research through Collaboration）のような共同研究ネットワークがあり、臨床試験開発や実臨床におけるエビデンスの創出が加速されています。欧州ではEuropean Reference Network on Rare Adult Solid Cancers（EURACAN）の下、複数の肉腫リファレンスネットワークが存在し、国境を越えた専門治療へのアクセスを強化しています。両地域とも希少がん治療薬に対する有利な償還政策と、希少がん研究を支援する強力な制度的枠組みが特徴です。

対照的に、アジア太平洋地域では、認知度の低さ、診断の遅れ、高度な診断ツールや治療へのアクセスの不均一さにより、STSの管理に大きな格差が生じています。しかし、インド、中国、東南アジアでは、ヘルスケアへの投資が増加し、民間の腫瘍センターが成長しているため、こうした格差は徐々に解消されつつあります。日本の製薬会社や病院は、脂肪肉腫や消化管間質腫瘍（GIST）の調査に顕著に関与しており、中国は世界の臨床試験パイプラインへの貢献度を高めています。ラテンアメリカや中東・アフリカ地域は診断や治療へのアクセスに制約があるが、国際的な非営利団体との協力や患者支援活動により、主要都市部では治療経路が改善されつつあります。

製薬会社もまた、サブタイプに特化したパイプラインを開発し、臨床試験へのアクセスを拡大するために学術機関と提携を結ぶことで、肉腫治療薬をめぐる商業戦略を再構築しています。希少疾病用医薬品の指定や、迅速承認、独占権の延長、研究開発税額控除などの関連する規制上の優遇措置は、超希少肉腫サブタイプをターゲットとするバイオベンチャーを後押ししています。デジタルヘルスプラットフォームやAIを活用した病理検査ツールも、早期発見の改善や病理検査ワークフローの迅速化のために、特にリソースの乏しい環境で導入されています。

軟部肉腫市場拡大の原動力は何か、どこにビジネスチャンスが生まれているのか？

世界の軟部肉腫市場の成長は、希少がんに対する認識の高まり、個別化腫瘍学の拡大、希少疾病用医薬品の開発を支援する規制の機運など、いくつかの要因によって牽引されています。病理組織学的検査や分子生物学的検査サービスの利用可能性が高まることで、診断精度が向上し、早期発見やより効果的な治療計画が可能になります。さらに、がんゲノミクスとトランスレーショナル・リサーチへの投資の増加により、サブタイプ特有の脆弱性が明らかになり、標的創薬への取り組みに拍車がかかっています。

希少疾患登録、助成金、学際的腫瘍委員会などを通じて、希少がん管理に対する政府や組織の支援は、患者の同定と臨床試験の募集を改善しています。リアルワールドエビデンスプラットフォームや世界肉腫患者データベースの導入も、市販後のサーベイランスを支援し、臨床的意思決定を助けています。これと並行して、製薬会社は遺伝的に定義されたSTSサブタイプに対する治療開発を迅速に進めるために適応試験デザインを採用しています。このような技術革新は、少人数の患者集団や不均一な臨床像の限界を克服するのに役立っています。

新たな機会は、デジタル病理学、AI支援画像解析、リキッドバイオプシーに基づくモニタリングの肉腫治療経路への統合にあります。これらのツールは診断精度を高め、腫瘍再発の非侵襲的モニタリングを容易にします。さらに、日常的な腫瘍診療における次世代シーケンシング・パネルとコンパニオン診断薬の使用拡大により、標的治療からより大きな価値が引き出されることが期待されます。製薬企業や診断企業が希少腫瘍のターゲットに集中し、医療制度が希少がんのインフラを強化し続けていることから、軟部肉腫市場は、科学的進歩、政策支援、拡大する患者参加の枠組みを原動力として、一貫した成長を遂げるものと位置づけられています。

セグメント

治療タイプ（標的療法治療、化学療法治療、血管新生阻害薬治療、放射線療法治療、その他の治療タイプ）、エンドユーザー（病院エンドユーザー、在宅医療エンドユーザー、専門施設エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Aadi Bioscience, Inc.
• Adaptimmune Therapeutics
• Advenchen Laboratories
• Agenus
• AstraZeneca
• Bayer AG
• Chipscreen Biosciences, Ltd.
• Chugai Pharma France
• Eli Lilly and Company
• Epizyme
• GSK（GlaxoSmithKline）
• Iovance Biotherapeutics
• Jazz Pharmaceuticals
• Mirati Therapeutics
• Nanobiotix
• Novartis
• Plus Therapeutics, Inc.
• Taiho Pharmaceuticals
• Thermosome GmbH（THE001）
• Tracon Pharmaceuticals Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Soft Tissue Sarcoma Market to Reach US$2.4 Billion by 2030

The global market for Soft Tissue Sarcoma estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2024-2030. Targeted Therapy Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$904.7 Million by the end of the analysis period. Growth in the Chemotherapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$417.6 Million While China is Forecast to Grow at 11.8% CAGR

The Soft Tissue Sarcoma market in the U.S. is estimated at US$417.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$502.8 Million by the year 2030 trailing a CAGR of 11.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Soft Tissue Sarcoma Market - Key Trends & Drivers Summarized

Targeting Complexity: Innovations in Diagnosis and Therapy Transforming Soft Tissue Sarcoma Management

What Makes Soft Tissue Sarcoma a Unique Therapeutic Challenge in Oncology?

Soft tissue sarcoma (STS) comprises a heterogeneous group of rare malignant tumors originating from connective tissues such as fat, muscle, blood vessels, nerves, and tendons. Representing less than 1% of all adult cancers, STS spans over 50 histologic subtypes, including liposarcoma, leiomyosarcoma, synovial sarcoma, and undifferentiated pleomorphic sarcoma. This histological diversity presents a significant challenge for oncologists, pathologists, and drug developers. Standardized treatment is often limited by the difficulty of early diagnosis, variable tumor behavior, and differing responses to therapeutic interventions. Most cases are diagnosed only after tumors reach advanced stages or metastasize, primarily due to their asymptomatic progression and misclassification with benign lesions.

Histopathological and molecular profiling have thus become indispensable in STS diagnosis. Immunohistochemistry, FISH (fluorescence in situ hybridization), and next-generation sequencing (NGS) are being increasingly employed to accurately characterize tumor subtypes and identify actionable genetic alterations. Advances in molecular diagnostics are now enabling personalized approaches to STS treatment. However, the rarity and complexity of these tumors continue to limit the availability of large-scale clinical trials, resulting in fewer approved targeted therapies compared to other cancers. The inherent genetic instability and adaptability of STS cells further complicate therapeutic strategies, often resulting in poor prognoses for patients with advanced disease.

Which Treatment Strategies and Therapeutic Developments Are Reshaping the STS Landscape?

Surgical resection remains the primary treatment modality for localized soft tissue sarcomas, often supplemented by radiotherapy and chemotherapy depending on tumor grade, location, and resection margins. In high-grade and deep-seated sarcomas, radiation therapy-either external beam or brachytherapy-is administered to reduce recurrence risk. However, systemic therapies for advanced and metastatic STS have traditionally been limited in efficacy. Doxorubicin-based chemotherapy, either alone or in combination with ifosfamide, has long been the frontline standard, but is often associated with significant toxicity and modest survival benefits.

Targeted therapy and immunotherapy are now driving the paradigm shift in STS treatment. Agents such as pazopanib, a multi-tyrosine kinase inhibitor, and trabectedin, a DNA-binding anti-neoplastic, are showing subtype-specific efficacy. For instance, pazopanib has demonstrated effectiveness in non-adipocytic STS, while eribulin has shown promise in liposarcoma patients. Moreover, immunotherapies such as PD-1 and CTLA-4 checkpoint inhibitors are under evaluation, particularly for subtypes like undifferentiated pleomorphic sarcoma and synovial sarcoma with higher mutational burdens. CAR-T cell therapy and cancer vaccines targeting cancer testis antigens are also being explored in preclinical and early-phase clinical trials.

Precision medicine is advancing further with biomarker-driven approaches. NTRK fusions, ALK rearrangements, and CDK4 amplifications are becoming targets for novel therapies, enabling drug repurposing across histologically distinct but genomically similar tumors. Companion diagnostics are being co-developed with these therapies to ensure accurate patient selection. Additionally, several academic-industry collaborations are pushing for pan-sarcoma registries and adaptive trial designs to overcome recruitment challenges and enable faster data accumulation across rare subtypes.

How Are Regional Healthcare Systems and Stakeholders Responding to Sarcoma Management Needs?

North America and Europe lead the global soft tissue sarcoma market in terms of diagnostics, research, and treatment access. The U.S. benefits from dedicated sarcoma centers and collaborative research networks such as the Sarcoma Alliance for Research through Collaboration (SARC), which accelerates clinical trial development and real-world evidence generation. Europe hosts several sarcoma reference networks under the European Reference Network on Rare Adult Solid Cancers (EURACAN), enhancing cross-border access to specialized care. Both regions are marked by favorable reimbursement policies for orphan drugs and strong institutional frameworks supporting rare cancer research.

In contrast, Asia Pacific exhibits significant disparity in STS management due to limited awareness, delayed diagnosis, and uneven access to advanced diagnostic tools and treatments. However, rising healthcare investments and the growth of private oncology centers in India, China, and Southeast Asia are gradually bridging these gaps. Japanese pharmaceutical firms and hospitals are notably involved in research on liposarcoma and gastrointestinal stromal tumors (GIST), while China is increasingly contributing to global clinical trial pipelines. Latin America and the Middle East & Africa regions face constraints in diagnosis and treatment access, but international non-profit collaborations and patient advocacy are improving care pathways in major urban centers.

Pharmaceutical companies are also reconfiguring their commercial strategies around sarcoma drugs by developing subtype-specific pipelines and forming partnerships with academic institutions to expand clinical trial access. The orphan drug designation and associated regulatory incentives-such as fast-track approvals, extended exclusivity, and R&D tax credits-are encouraging biotech startups to target ultra-rare sarcoma subtypes. Digital health platforms and AI-driven pathology tools are also being deployed to improve early detection and accelerate pathology workflows, especially in under-resourced settings.

What Is Driving the Expansion of the Soft Tissue Sarcoma Market and Where Are Opportunities Emerging?

The growth in the global soft tissue sarcoma market is driven by several factors including increasing awareness of rare cancers, expansion of personalized oncology, and the regulatory momentum supporting orphan drug development. The rising availability of histopathology and molecular testing services is leading to improved diagnostic accuracy, enabling early-stage detection and more effective treatment planning. Furthermore, increasing investments in cancer genomics and translational research are uncovering subtype-specific vulnerabilities, spurring targeted drug discovery efforts.

Governmental and institutional support for rare cancer management-through rare disease registries, funding grants, and interdisciplinary tumor boards-is improving patient identification and clinical trial recruitment. The introduction of real-world evidence platforms and global sarcoma patient databases is also supporting post-market surveillance and aiding clinical decision-making. In parallel, pharmaceutical companies are adopting adaptive trial designs to fast-track development of treatments for genetically defined STS subtypes. These innovations are helping overcome the limitations of small patient pools and heterogeneous clinical presentations.

Emerging opportunities lie in integrating digital pathology, AI-assisted image analysis, and liquid biopsy-based monitoring into sarcoma care pathways. These tools can enhance diagnostic precision and facilitate non-invasive monitoring of tumor recurrence. Additionally, the growing use of next-generation sequencing panels and companion diagnostics in routine oncology practice is expected to unlock greater value from targeted therapies. As pharmaceutical and diagnostic players converge around rare tumor targets, and health systems continue to enhance rare cancer infrastructure, the soft tissue sarcoma market is positioned for consistent growth, driven by scientific advances, policy support, and expanding patient engagement frameworks.

SCOPE OF STUDY:

The report analyzes the Soft Tissue Sarcoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment, Other Treatment Types); End-Use (Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Aadi Bioscience, Inc.
• Adaptimmune Therapeutics
• Advenchen Laboratories
• Agenus
• AstraZeneca
• Bayer AG
• Chipscreen Biosciences, Ltd.
• Chugai Pharma France
• Eli Lilly and Company
• Epizyme
• GSK (GlaxoSmithKline)
• Iovance Biotherapeutics
• Jazz Pharmaceuticals
• Mirati Therapeutics
• Nanobiotix
• Novartis
• Plus Therapeutics, Inc.
• Taiho Pharmaceuticals
• Thermosome GmbH (THE001)
• Tracon Pharmaceuticals Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Soft Tissue Sarcoma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Rare Cancer Types Drives Investment in Soft Tissue Sarcoma Treatments
  • Growth in Personalized Oncology Enhances Molecular Targeting Approaches
  • Increased Use of Radiotherapy and Chemotherapy Combinations Boosts Treatment Uptake
  • Expansion of Immunotherapy Clinical Trials Spurs Therapeutic Advancements
  • FDA and EMA Orphan Drug Designations Accelerate Market Entry
  • Development of Biomarkers for Sarcoma Subtypes Supports Diagnostic Precision
  • Growing Adoption of Next-Generation Sequencing Enables Genetic Profiling
  • Collaborative Research Efforts Fuel Drug Discovery and Repurposing Initiatives
  • Patient Advocacy Group Involvement Improves Clinical Trial Enrollment
  • Integration of Digital Pathology Tools Enhances Diagnostic Accuracy
  • Rise in Multidisciplinary Cancer Care Centers Broadens Access to Sarcoma Therapies
  • Public-Private Partnerships Facilitate R&D in Rare Cancer Segments
  • Expansion of Soft Tissue Sarcoma Registries Strengthens Data-Driven Insights
  • Surge in Targeted Therapy Approval Rates Encourages Pharmaceutical Investment
  • Use of Robotic-Assisted Surgery Enhances Tumor Resection Outcomes
  • Increasing Insurance Coverage for Rare Cancers Expands Patient Accessibility
  • High Demand for Post-Treatment Monitoring Fuels Companion Diagnostic Development
  • Scientific Advances in Tumor Microenvironment Research Propel Innovation
  • Focus on Limb-Sparing Procedures Increases Need for Adjuvant Therapies
  • International Collaboration on Treatment Guidelines Promotes Standardized Care Pathways
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Soft Tissue Sarcoma Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Soft Tissue Sarcoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Targeted Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Targeted Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Anti-Angiogenesis Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Anti-Angiogenesis Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Homecare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Homecare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: China 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Soft Tissue Sarcoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: France 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Soft Tissue Sarcoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: India 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Soft Tissue Sarcoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Soft Tissue Sarcoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Soft Tissue Sarcoma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Soft Tissue Sarcoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Soft Tissue Sarcoma by Treatment Type - Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Soft Tissue Sarcoma by Treatment Type - Percentage Breakdown of Value Sales for Targeted Therapy Treatment, Chemotherapy Treatment, Anti-Angiogenesis Drugs Treatment, Radiation Therapy Treatment and Other Treatment Types for the Years 2014, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Soft Tissue Sarcoma by End-Use - Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Soft Tissue Sarcoma by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare End-Use, Specialty Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION